Proto-Oncogene Proteins p21(ras)
"Proto-Oncogene Proteins p21(ras)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cellular proteins encoded by the H-ras, K-ras and N-ras genes. The proteins have GTPase activity and are involved in signal transduction as monomeric GTP-binding proteins. Elevated levels of p21 c-ras have been associated with neoplasia. This enzyme was formerly listed as EC 3.6.1.47.
Descriptor ID |
D016283
|
MeSH Number(s) |
D08.811.277.040.330.300.400.500.600 D12.644.360.525.500.600 D12.776.157.325.515.500.600 D12.776.476.525.500.600 D12.776.624.664.700.200
|
Concept/Terms |
Proto-Oncogene Proteins p21(ras)- Proto-Oncogene Proteins p21(ras)
- p21 c-ras
- c-ras, p21
- p21 c ras
- p21(c-ras)
- ras Proto-Oncogene Protein p21
- ras Proto Oncogene Protein p21
- Proto-Oncogene Proteins c-ras
- Proteins c-ras, Proto-Oncogene
- Proto Oncogene Proteins c ras
- c-ras, Proto-Oncogene Proteins
- Proto-Oncogene Protein ras
- Proto Oncogene Protein ras
- ras, Proto-Oncogene Protein
- ras Proto-Oncogene Product p21
- ras Proto Oncogene Product p21
- c-ras Proteins
- c ras Proteins
- p21(ras)
- Proto-Oncogene Protein p21(ras)
Proto-Oncogene Protein p21(c-Ha-ras)- Proto-Oncogene Protein p21(c-Ha-ras)
- p21 c-Ha-ras
- c-Ha-ras, p21
- p21 c Ha ras
- p21(c-Ha-ras)
- p21 c-H-ras
- c-H-ras, p21
- p21 c H ras
- c-Ha-ras p21
- c Ha ras p21
- p21, c-Ha-ras
Proto-Oncogene Protein p21(c-Ki-ras)- Proto-Oncogene Protein p21(c-Ki-ras)
- p21 c-Ki-ras
- c-Ki-ras, p21
- p21 c Ki ras
- p21(c-Ki-ras)
- p21 c-K-ras
- c-K-ras, p21
- p21 c K ras
- c-Ki-ras p21
- c Ki ras p21
- p21, c-Ki-ras
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins p21(ras)".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins p21(ras)".
This graph shows the total number of publications written about "Proto-Oncogene Proteins p21(ras)" by people in this website by year, and whether "Proto-Oncogene Proteins p21(ras)" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 1 | 2 | 3 | 1994 | 1 | 2 | 3 | 1995 | 1 | 1 | 2 | 1996 | 3 | 4 | 7 | 1997 | 5 | 4 | 9 | 1998 | 1 | 2 | 3 | 1999 | 2 | 1 | 3 | 2000 | 2 | 0 | 2 | 2001 | 2 | 0 | 2 | 2002 | 0 | 1 | 1 | 2003 | 0 | 1 | 1 | 2004 | 1 | 1 | 2 | 2006 | 3 | 2 | 5 | 2007 | 1 | 0 | 1 | 2008 | 2 | 4 | 6 | 2009 | 0 | 6 | 6 | 2010 | 0 | 3 | 3 | 2011 | 0 | 4 | 4 | 2012 | 1 | 6 | 7 | 2013 | 2 | 8 | 10 | 2014 | 0 | 5 | 5 | 2015 | 3 | 4 | 7 | 2016 | 0 | 3 | 3 | 2017 | 6 | 1 | 7 | 2018 | 0 | 6 | 6 | 2019 | 6 | 3 | 9 | 2020 | 1 | 2 | 3 | 2021 | 3 | 2 | 5 | 2022 | 1 | 2 | 3 | 2023 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins p21(ras)" by people in Profiles.
-
Sheppard SE, March ME, Seiler C, Matsuoka LS, Kim SE, Kao C, Rubin AI, Battig MR, Khalek N, Schindewolf E, O'Connor N, Pinto E, Priestley JR, Sanders VR, Niazi R, Ganguly A, Hou C, Slater D, Frieden IJ, Huynh T, Shieh JT, Krantz ID, Guerrero JC, Surrey LF, Biko DM, Laje P, Castelo-Soccio L, Nakano TA, Snyder K, Smith CL, Li D, Dori Y, Hakonarson H. Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition. JCI Insight. 2023 05 08; 8(9).
-
Iams WT, Balbach ML, Phillips S, Sacher A, Bestvina C, Velcheti V, Wang X, Marmarelis ME, Sethakorn N, Leal T, Sackstein PE, Kim C, Robinson MA, Mehta K, Hsu R, Nieva J, Patil T, Camidge DR. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer. Clin Lung Cancer. 2023 05; 24(3):228-234.
-
Claire Hou YC, Evenson MJ, Corliss MM, Mahapatra L, Aldawood A, Carpentieri DF, Chamlin SL, Kulungowski AM, Madan-Khetarpal S, Sebastian J, Pet MA, Coughlin CC, Willing MC, Pearson GD, Setty BA, El-Haffaf Z, Cottrell CE, Parikh BA, Krysiak K, Schroeder MC, Heusel JW, Neidich JA, Cao Y. A comparative analysis of RAS variants in patients with disorders of somatic mosaicism. Genet Med. 2023 03; 25(3):100348.
-
Vu NT, Kim M, Stephenson DJ, MacKnight HP, Chalfant CE. Ceramide Kinase Inhibition Drives Ferroptosis and Sensitivity to Cisplatin in Mutant KRAS Lung Cancer by Dysregulating VDAC-Mediated Mitochondria Function. Mol Cancer Res. 2022 09 02; 20(9):1429-1442.
-
J?nne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022 07 14; 387(2):120-131.
-
Ferrero E, Villa A, Stefanoni D, Nemkov T, D'Alessandro A, Tengesdal I, Belloni D, Molteni R, Vergani B, De Luca G, Grassini G, Cangi MG, Dagna L, Doglioni C, Cavalli G, Ferrarini M. Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis. Rheumatology (Oxford). 2022 04 11; 61(4):e93-e96.
-
Mickler EA, Zhou H, Phang TL, Geraci MW, Stearman RS, Sears CR. Low-Coverage Whole Genome Sequencing Using Laser Capture Microscopy with Combined Digital Droplet PCR: An Effective Tool to Study Copy Number and Kras Mutations in Early Lung Adenocarcinoma Development. Int J Mol Sci. 2021 Nov 06; 22(21).
-
Sturmlechner I, Zhang C, Sine CC, van Deursen EJ, Jeganathan KB, Hamada N, Grasic J, Friedman D, Stutchman JT, Can I, Hamada M, Lim DY, Lee JH, Ordog T, Laberge RM, Shapiro V, Baker DJ, Li H, van Deursen JM. p21 produces a bioactive secretome that places stressed cells under immunosurveillance. Science. 2021 Oct 29; 374(6567):eabb3420.
-
Kurth I, Yamaguchi N, Andreu-Agullo C, Tian HS, Sridhar S, Takeda S, Gonsalves FC, Loo JM, Barlas A, Manova-Todorova K, Busby R, Bendell JC, Strauss J, Fakih M, McRee AJ, Hendifar AE, Rosen LS, Cercek A, Wasserman R, Szarek M, Spector SL, Raza S, Tavazoie MF, Tavazoie SF. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Sci Adv. 2021 10 08; 7(41):eabi7511.
-
Gao S, Nelson J, Weinsheimer S, Winkler EA, Rutledge C, Abla AA, Gupta N, Shieh JT, Cooke DL, Hetts SW, Tihan T, Hess CP, Ko N, Walcott BP, McCulloch CE, Lawton MT, Su H, Pawlikowska L, Kim H. Somatic mosaicism in the MAPK pathway in sporadic brain arteriovenous malformation and association with phenotype. J Neurosurg. 2022 01 01; 136(1):148-155.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|